PATENT CLAIM ANALYSIS

Application Number: 16126772
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-06
Patent Classification: ["530", "300000"]

Abstract:
Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.

Claim (Index 13):
The method of  claim 10 , wherein the tissue is obtained from a tumor.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.64286
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15162598', '13529875', '15155912', '13976956', '15156289']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7833822967945462
- 35 USC 102 Novelty (BERT): 0.5640823623838142
- Combined Prediction Score: 0.761452303353473
- Mean Citation Score: 469.228014
- Max Citation Score: 522.3496
- Similarity Product: 331.1498154910088

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test